HYDERGINE
LOE ApproachingNDAORALSOLUTION
Approved
Jan 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is an oral solution small-molecule NDA approved in 1981 by Novartis. The specific mechanism of action and therapeutic indications are not documented in available data. It is positioned as a legacy branded product approaching loss of exclusivity.
LOE Approaching
Product is in late-stage commercial lifecycle with moderate competitive pressure (30%), indicating defensive positioning and potential team restructuring as LOE nears.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYDERGINE currently shows zero linked job openings, reflecting its mature lifecycle stage and approaching LOE. Career opportunities on this product are limited to defensive commercial roles focused on maximizing margins during exclusivity erosion.
Brand ManagerProduct Manager
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.